JERUSALEM, November 15 (Xinhua) – Israel's researchers have developed a treatment that could prevent developmental restraint and autism, a report issued by Tel Aviv University said on Thursday.
The researchers found that early therapy with the NAP peptide (nucleusome nucleus protein) normalizes the development of mice in a model of ADNP syndrome (which is dependent on activity that is suffering from neuropatholic protein) in children.
This genetic migration is one of the main causes of developmental delay and autism in children.
The ADNP gene plays a part in the development of cognition. Emotions with a partial ADNP deficiency will suffer to revoke mind and, in most cases, autism.
In recent years, with genetic progression technology, autistic children with mental slowdown had random convictions in the ADNP gene, which appear during pregnancy.
The resulting protein is shorter than usual, and as a result, children suffer from incomplete ADNP (namely ADNP syndrome).
The researchers found that mice with ADNP only produce about half the number of synapses (the contact points between nerve cells) compared to healthy mice – especially in the brain areas responsible for cognitive activity, according to the report.
These mice showed developmental delays, social difficulty, and sensitivity, such as children with mental slowdown and autism.
During the next stage, the NAP peptide was injected daily to the mice affected by the time of birth, followed by nauseous spray to weakened lactative breastfeeding.
The results were very impressive: the mice have been treated, unlike those that have not been treated, have usually been developed. They made voices to call their mothers, walking, with an appropriate memory, can distinguish between familiar and unfamiliar mice, and develop strength in their muscles.
It also turned out that the brain of these mice begins to produce an appropriate number of synapses.